Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) was the recipient of some unusual options trading activity on Tuesday. Investors purchased 41,192 call options on the company. This is an increase of 79% compared to the average volume of 23,034 call options.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BMY. Barclays began coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Trading Down 0.8%

Shares of NYSE BMY traded down $0.46 during midday trading on Tuesday, reaching $54.34. 20,569,950 shares of the stock were exchanged, compared to its average volume of 9,806,476. The business has a 50-day simple moving average of $58.25 and a two-hundred day simple moving average of $56.37. The company has a market capitalization of $110.97 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period last year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts expect that Bristol Myers Squibb will post 6.31 EPS for the current year.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced that Opdivo plus AVD received an expanded EU label for frontline advanced classical Hodgkin lymphoma, potentially broadening access and boosting revenue for a major franchise. Article Title
• Positive Sentiment: The FDA accepted Camzyos for priority review in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, keeping another growth product on track for a potential label expansion. Article Title
• Positive Sentiment: New ASCO data showed encouraging results for mezigdomide and pumitamig, reinforcing investor optimism around BMY’s late-stage pipeline beyond legacy brands. Article Title
• Neutral Sentiment: Unusually heavy call-option buying suggests traders are positioning for a move higher, but it does not confirm a fundamental change in the business.
• Neutral Sentiment: Analysts and commentators continue to debate BMY’s valuation, with some arguing the stock looks inexpensive while others warn that patent expirations will pressure results through 2028. Article Title
• Negative Sentiment: Recent valuation-focused coverage notes that the stock has pulled back over the past week and month, reflecting ongoing investor concern about growth after the patent cycle. Article Title

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently made changes to their positions in BMY. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares during the period. Bayban acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.